Abstract:Abstract Abstract 3625 Poster Board III-561 The hematopoietic microenvironment plays an important role during stem cell homeostasis and in disease. With an improved understanding, new ways to modulate cellular and molecular targets in the microenvironment have become increasingly important. Cell-derived microvesicles (exosomes) have recently attracted interest in immune and cancer biology for their ability to transmit protein and nucleic acid content between cells. We described the ability of VSV-G pseudotyped lentivector to access intracellular multivesicular bodies (MVB) in primary (hematopoietic and non-hematopoietic) cells, with subsequent transfer to secondary (2°) cells (Skinner et. al., PLoS One, 2009). Specifically, we demonstrated that during vector trafficking in non immune target cells, a minority of replication incompetent particles are sequestered in a non-canonical, tetraspanin-associated cytoplasmic compartment. Particles are refractory to envelope (VSV-G) neutralization, susceptible to pharmacological inhibition of PI-3 kinase and capable of transmission to 2° cells. We therefore hypothesized that lentivector particles captured in exosomes and delivered to the bone marrow via homed hematopoietic carriers could be used for the deliberate genetic modification of the hematopoietic microenvironment. To ascertain trafficking of lentivector in exosomes, we imaged particles within vesicles using electron microscopy of vector-exposed human K562 myeloid leukemia cells. In addition, we exposed K562 cells to GFP-vpr fusion protein tagged vector particles and the exosome tracer N-rhodamine- phosphatidylethanolamine (N-Rh-PE), purified exosomes and observed colocalization of GFP-vpr (particles) with N-Rh-PE (exosomes) by deconvolution fluorescent microscopy. We next wished to test the exosomal delivery for the genetic marking of murine stromal cells in situ. We isolated whole bone marrow from CD45.1 mice, exposed these cells to GFP transfer vector for 1 hour (MOI 5), removed residual surface-bound particles and injected cells into tail veins of five non-irradiated, congenic CD45.2 animals. At the time of sacrifice, whole bone marrow, spleen, peripheral blood, and multiple other organs were analyzed by quantitative real time PCR, revealing preferential vector marking in the hematopoietic organs. To determine if lentivector particles were delivered to non-hematopoietic elements in the bone marrow, adherent stromal cells were isolated 15 weeks after transplantation, plated at varying densities per well in 6-well plates, and cultured in vitro. We generated 13-15 CFU-F colonies per 1×105 cells and used fluorescent microscopy to image GFP expression. We observed GFP-expressing stromal cells from an initial cohort of 5 animals, ranging in frequency from 24-87% of pooled CFU-F cells examined. Using semi-quantitative PCR, we amplified GFP sequence from individual colonies, confirming that these stromal cells were genetically modified in all animals. To confirm that the isolated stromal cells were of host origin, we developed a single nucleotide polymorphism (SNP) PCR strategy to differentiate cells of donor versus host origin. Additional cohorts are undergoing analysis. In conclusion, we propose a model in which lentivector is trafficked into exosomes and delivered to hematopoietic microenvironment via homed carrier cells. Future experiments will optimize the efficiency of delivery. Successful cellular delivery of rationally designed vector particles to the hematopoietic microenvironment may offer one potential strategy to facilitate manipulation of the stem cell niche in vivo. Disclosures: No relevant conflicts of interest to declare.

Brain-Wide Transgene Expression in Mice by Systemic Injection of Genetically Engineered Exosomes: CAP-Exosomes

The Antitumor Effect of Gene-Engineered Exosomes in the Treatment of Brain Metastasis of Breast Cancer.

Stable, neuron-specific gene expression in the mouse brain

Intracerebroventricular Administration of AAV9-PHP.B SYN1-EmGFP Induces Widespread Transgene Expression in the Mouse and Monkey Central Nervous System

Functional gene delivery to and across brain vasculature of systemic AAVs with endothelial-specific tropism in rodents and broad tropism in primates

Ultrasound-Mediated Blood-Brain Barrier Opening Improves Whole Brain Gene Delivery in Mice

Intranasal Delivery and Transfection of mRNA Therapeutics in the Brain Using Cationic Liposomes.

The Glymphatic System Delivery Enhances the Transduction Efficiency of AAV1 to Brain Endothelial Cells in Adult Mice.

An Exosome Delivery Strategy for the Genetic Modification of the Hematopoietic Microenvironment.

Ddel-01. Engineering Mrna Therapies For Brain Tumors

Large-scale generation of functional mRNA-encapsulating exosomes via cellular nanoporation

Expression-based selection identifies a microglia-tropic AAV capsid for direct and CSF routes of administration in mice

Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes

Engineered exosomes derived from stem cells: a new brain-targeted strategy

Engineered Exosomes: A Promising Drug Delivery Strategy for Brain Diseases

Exomap1 mouse: A transgenic model for in vivo studies of exosome biology

Engineered parasite delivers therapeutic proteins to the mouse brain

In Vivo Introduction of mRNA Encapsulated in Lipid Nanoparticles to Brain Neuronal Cells and Astrocytes via Intracerebroventricular Administration

Engineered exosomes with a photoinducible protein delivery system enable CRISPR-Cas-based epigenome editing in Alzheimer's disease

Harnessing Exosomes for the Development of Brain Drug Delivery Systems

Exosomes as a Nanodelivery System: a Key to the Future of Neuromedicine?